Epigral Reports Mixed Financial Results Amid Growth and Operational Challenges in August 2025

Epigral, a midcap player in the specialty chemicals industry, has released its financial results for the quarter ending June 2025 on August 2, 2025. The evaluation changes indicate a notable shift in the stock's score, which has seen a revision from 11 to 1 over the past three months.
The financial results reveal several positive aspects for Epigral. The Profit After Tax (PAT) reached Rs 160.69 crore, marking a significant growth compared to the average of the previous four quarters. This figure represents the highest PAT recorded in the last five quarters, suggesting a favorable near-term trend. Additionally, the Earnings per Share (EPS) also hit a peak at Rs 37.25, reflecting enhanced profitability for shareholders. Furthermore, the company has achieved its lowest Debt-Equity Ratio at 0.31 times in the last five half-yearly periods, indicating a reduction in borrowing relative to equity capital.

Conversely, there are areas of concern. The Profit Before Tax less Other Income (PBT) has shown a decline, falling to Rs 98.76 crore, which is the lowest in the last five quarters. The inventory turnover ratio has also reached its lowest point, suggesting a slowdown in the pace of selling inventory. Additionally, net sales have decreased to Rs 606.54 crore, and the operating profit margin has contracted to 26.94%, indicating challenges in operational efficiency.

Overall, Epigral's financial results reflect a complex landscape of growth in certain areas while facing significant challenges in others.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.